First patient enrolled in phase-IIa study of vamifeport in p

Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult patients with sickle cell disease.

Related Keywords

United States , United Kingdom , Switzerland , Greece , Lebanon , Swiss , Vifor Pharma , Julien Vignot , Klaus Henning Jensen , Nathalie Ponnier , Swiss Stock Exchange , Drug Administration , Global Head Corporate Communications , Swiss Exchange , Vifor Pharma Group , European Medicines Agency , Fresenius Medical Care , Chief Medical Officer , Pharma Group , Vifor Fresenius Medical Care Renal Pharma , Media Contact , Head Corporate Communications , Investor Relations , Amifeport , Sickle Cell Disease , Ral Ferroportin Inhibitor , Red Blood Cells , Rare Blood Disorder , Treatment Options , Hase Iia Clinical Trial , Us Food And Drug Administration , Beta Thalassemia , Haemoglobin , Pharmaceuticals ,